MedTrace Logo

Bioavailability Study of XS003 (Nilotinib)

NCT07138352 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-08-22

No results posted yet for this study

Summary

An open label, single-center, randomized, two-treatment, two-period, two-sequence, single dose, crossover, study under fasted and fed conditions.

Conditions

Interventions

DRUG

XS003 under fed and fasted condition

XS003 under fed and fasted condition

Sponsors & Collaborators

  • Xspray Pharma AB

    lead INDUSTRY

Principal Investigators

  • Maria Klockare · Xspray Pharma

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-10-03
Primary Completion
2025-01-08
Completion
2025-01-08
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07138352 on ClinicalTrials.gov